Clinical TrialJul 22, 2026, 07:01 AM
Radiopharm RAD101 Phase 2b Meets Endpoint; RAD204 Phase 1 Partial Response
AI Summary
Radiopharm Theranostics announced positive results from two clinical trials. Its RAD101 Phase 2b trial for diagnosing brain metastases met its primary endpoint, showing 93% concordance with MRI and 86% preliminary sensitivity. The company plans to advance RAD101 to a U.S. Phase 3 pivotal trial in Q4 2026. Additionally, the Phase 1 trial of RAD204 for advanced solid tumors achieved a confirmed durable partial response in one patient, who remained progression-free for over seven months, with no dose-limiting toxicities observed.
Key Highlights
- RAD101 Phase 2b trial met its primary endpoint with 93% concordance with MRI for brain metastases.
- RAD101 showed preliminary 86% sensitivity (12/14 patients) in identifying tumor recurrence.
- Radiopharm plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026.
- RAD204 Phase 1 trial achieved a confirmed durable partial response in one patient.
- The patient treated with RAD204 remained progression-free beyond seven months.
- RAD204 was generally well-tolerated with no dose-limiting toxicities observed.
Price Impact
More from RADX